Chemomab Therapeutics Ltd (CMMB)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current CMMB market cap is 19.46M. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.05M | -8.2M | -4.37M | -3.85M | -4.05M |
| Net Income | -8.75M | -7.97M | -4.08M | -3.42M | -3.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -22.9M | -11.71M | -12.37M | -28.53M | -25.46M |
| Net Income | -27.12M | -11.61M | -12.48M | -27.65M | -24.22M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 35.01M | 28.85M | 23.42M | 22.15M | 18.01M |
| Total Liabilities | 7.06M | 6.86M | 5.38M | 5.16M | 4.68M |
| Total Equity | 27.95M | 21.99M | 18.04M | 17M | 13.33M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 19.76M | 6.18M | 64.35M | 43.06M | 22.15M |
| Total Liabilities | 4.85M | 2.6M | 2.89M | 6.84M | 5.15M |
| Total Equity | 14.91M | 3.58M | 61.47M | 36.22M | 17M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -7.19M | -14.67M | -19.89M | N/A | N/A |
| Investing | 14.43M | 10.16M | 14.16M | N/A | N/A |
| Financing | N/A | 1.37M | 1.37M | N/A | N/A |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -16.46M | -12.71M | -12.37M | -20.37M | -23.61M |
| Investing | -95k | 102k | -45.19M | 19.53M | 15.88M |
| Financing | 26.62M | 297k | 61.07M | -808k | 3.5M |
| Market Cap | 19.46M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 14.2M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.08 (5.59%) |
| Company Name | Chemomab Therapeutics Ltd |
| Address |
kiryat atidim, building 7 tel aviv, center 6158002 |
| Website | https://www.chemomab.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
